Carl Icahn went public Tuesday morning, August 7, with his campaign against Cigna’s US$54 billion plan to buy Express Scripts. The billionaire activist investor sent an open letter urging fellow Cigna shareholders to vote against the deal.
Icahn called the deal a “$60 billion folly” carrying a “ridiculous” price tag, according to a draft seen by The Wall Street Journal.
CPI previously reported that Mr. Icahn bought a sizable Cigna stake, plans to vote against the health insurer’s proposed purchase of the pharmacy-benefit manager, and was considering publicly airing his concerns to persuade other shareholders to do the same.
His concerns include competitive risk from Amazon and indications from the Trump administration that it could limit the manufacturer rebates pharmacy-benefit managers get.
Full Content: The Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
EU Extends Support for Farms and Fisheries Amid Market Disruptions
May 5, 2024 by
CPI
Sony and Apollo Bid $26 Billion for Paramount Acquisition
May 5, 2024 by
CPI
Goldman Sachs Resolves Decade-Old Metal-Rigging Class Action Lawsuit
May 5, 2024 by
CPI
Italian Antitrust Ruling Puts Halt on Intesa Sanpaolo’s Fintech Ambitions
May 5, 2024 by
CPI
Google Antitrust Case: Closing Arguments Conclude
May 5, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI